Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis

Kazuhisa Furue; Takamichi Ito; Masutaka Furue

doi:10.1016/j.cyto.2018.08.025

Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis

Cytokine. 2018 Nov:111:182-188. doi: 10.1016/j.cyto.2018.08.025. Epub 2018 Aug 29.

Authors

Kazuhisa Furue¹, Takamichi Ito¹, Masutaka Furue²

Affiliations

¹ Department of Dermatology, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan.
² Department of Dermatology, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan; Division of Skin Surface Sensing, Department of Dermatology, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan; Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan. Electronic address: furue@dermatol.med.kyushu-u.ac.jp.

PMID: 30172115
DOI: 10.1016/j.cyto.2018.08.025

Abstract

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.

Keywords: Biologics, efficacy; Psoriasis; Psoriatic arthritis; TNF-α/IL-23/IL-17 axis.

Publication types

Review

MeSH terms

Arthritis, Psoriatic / metabolism*
Humans
Interleukin-17 / metabolism*
Interleukin-23 / metabolism*
Psoriasis / metabolism*
Skin / metabolism
Tumor Necrosis Factor-alpha / metabolism*

Substances

Interleukin-17
Interleukin-23
Tumor Necrosis Factor-alpha